Last Updated: June 25, 2026

Patent: 12,060,590

✉ Email this page to a colleague

Summary for Patent: 12,060,590

Title:	PH20 polypeptide variants, formulations and uses thereof
Abstract:	Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Inventor(s):	Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Assignee:	Halozyme Inc , Halozyme Therapeutics Inc
Application Number:	US18/068,218
Patent Claims:	see list of patent claims

Details for Patent 12,060,590

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005	⤷ Start Trial	2042-12-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 12,060,590

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2012362141	⤷ Start Trial
Australia	2017245352	⤷ Start Trial
Brazil	112014016195	⤷ Start Trial
Canada	2861919	⤷ Start Trial
China	104244968	⤷ Start Trial
Cyprus	1122532	⤷ Start Trial
Denmark	2797622	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.